Benmelstobart
As of the edition of 20 October 2026, Benmelstobart is an antibody: in active development; acts on CD274.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 79, 3 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | Q9NZQ7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 1 | 0 |
| Phase 1 | 5 | 0 | 0 | 0 |
| Phase 2 | 53 | 2 | 30 | 3 |
| Phase 3 | 18 | 0 | 8 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 79 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Chia Tai Tianqing Pharmaceutical | Lead sponsor of trials | 2018 to now |
| Tide Pharmaceutical | Lead sponsor of trials | 2025 to now |